Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Potential Cures of Alzheimer's Dementia
share announcement

Potential Cures of Alzheimer's Dementia

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1165

Special Issue Editor

Prof. Dr. Jeffrey Fessel

E-Mail Website
Guest Editor
Department of Medicine, University of California, 2069 Filbert Street, San Francisco, CA 94123, USA
Interests: Alzheimer’s dementia; schizophrenia; long COVID and mental symptoms; HIV/AIDS; rheumatic disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Several thousand reports detail information concerning potential causes of Alzheimer’s dementia (AD). Surely, a cure for this form of dementia must be attainable, which is why a Special Issue of the Journal of Clinical Medicine invites articles showing potential cures. Curing any medical condition has two generic approaches. The first treats all of the possible causes that contribute to pathogenesis; this requires dozens of drugs. AD may have >15 possible causes requiring >30 drugs, which could be administered sequentially in small numbers over a long period of time. Most of the few articles published about curing AD have proposed that approach. However, AD clearly has multiple causes, and these may differ from patient to patient, so a ‘one size fits all’ approach might be incorrect. A second approach avoids this by identifying, for each separate patient, only those components of pathogenesis that are actually operative. Articles using either approach are welcome.

Dr. Jeffrey Fessel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s dementia
  • cure
  • therapeutic approaches
  • clinical assessment
  • diagnosis
  • treatment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

9 pages, 252 KiB  
Review
All GLP-1 Agonists Should, Theoretically, Cure Alzheimer’s Dementia but Dulaglutide Might Be More Effective Than the Others
by Jeffrey Fessel
J. Clin. Med. 2024, 13(13), 3729; https://doi.org/10.3390/jcm13133729 - 26 Jun 2024
Viewed by 898
Abstract
Addressing the dysfunctions of all brain cell types in Alzheimer’s disease (AD) should cure the dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for GLP-1 are present in all of the main brain cell types, i.e., neurons, oligodendroglia, [...] Read more.
Addressing the dysfunctions of all brain cell types in Alzheimer’s disease (AD) should cure the dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for GLP-1 are present in all of the main brain cell types, i.e., neurons, oligodendroglia, astroglia, microglia, endothelial cells and pericytes. This article describes the benefits provided to all of those brain cell types by GLP-1 agonist drugs. The article uses studies in humans, not rodents, to describe the effect of GLP-1 agonists upon cognition, because rodents’ brains differ from those of humans in so many ways that results from rodent studies may not be totally transferable to humans. Commercially available GLP-1 agonists have mostly shown either positive effects upon cognition or no effects. One important reason for no effects is a reduced rate of entering brain parenchyma. Dulaglutide has the greatest entry to brain, at 61.8%, among the available GLP-1 agonists, and seems to offer the best likelihood for cure of AD. Although there is only one study of cognition that used dulaglutide, it was randomized, placebo controlled, and very large; it involved 8828 participants and showed significant benefit to cognition. A clinical trial to test the hypothesis that dulaglutide may cure AD should have, as its primary outcome, a 30% greater cure rate of AD by dulaglutide than that achieved by an equipoise arm of, e.g., lithium plus memantine. Full article
(This article belongs to the Special Issue Potential Cures of Alzheimer's Dementia)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop